Oct 24 (Reuters) – Johnson & Johnson on Saturday said its experimental once-daily oral prostate cancer drug caused tumors to disappear or shrink in an early-stage trial. J&J had gained access to the
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
VIDEO SHOWS: HIGHLIGHTS FROM OKLAHOMA CITY THUNDER'S WIN OVER THE LOS ANGELES CLIPPERS AS THUNDER…
Oct 26 (Reuters) - Verizon raised its annual forecast for wireless subscriber additions on Monday,…
SAO PAULO, Oct 26 (Reuters) - Brazilian lender Itau said on Monday it had entered…
Oct 26 (Reuters) - China Aluminum International Engineering Corp Ltd: * SAYS IT WON BINH…
(Recasts to lead with zinc; adds analyst comment, updates prices) Oct 26 (Reuters) - Zinc…
VIDEO SHOWS: HIGHLIGHTS FROM OKLAHOMA CITY THUNDER'S WIN OVER THE LOS ANGELES CLIPPERS AS THUNDER…